Immatics share price logo

Immatics

NASDAQ: IMTX

Small Cap

$8.95

+0.40

(+4.68%)

as on

Immatics Stock Performance

as on August 22, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $8.62
    $9.03
    downward going graph

    3.69%

    Downside

    0.89%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.05
    $12.41
    downward going graph

    43.58%

    Downside

    38.66%

    Upside

    downward going graph

Immatics share price movements today

Previous Close
$8.55
Open
$8.62
Volume
525.7K
Market Cap
$1.3B
Day's Low - High
$8.62 - $9.03
52 Week Low - High
$5.05 - $12.41

Immatics Historical Returns

1 Month Return
-1.56 %
3 Month Return
-13.16 %
1 Year Return
+ 49.13 %
3 Year Return
-18.62 %
5 Year Return
-22.24 %

Immatics Stock Fundamentals & Key Indicators

Check Immatics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-1.71

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.86

Industry PE ratio

-7.283372093023256

PEG Ratio

0.04333862334667386

EBITDA

-202.4M

Revenue (TTM)

37.3M

Profit Margin

100.00%

Return On Equity TTM

-45.27%

Immatics Stock Valuation

Track how Immatics P/E has moved over time to understand its valuation trends.

Immatics in the last 5 years

  • Overview

  • Trends

Lowest (-7.91x)

December 31, 2023

Industry (-7.28x)

December 31, 2025

Today (-5.80x)

December 31, 2025

Highest (49.04x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -5.80x

Immatics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immatics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Immatics image
Immatics
BUY$1.3B-22.24%-4.86100.00%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Moderna image
Moderna
BUY$25.3B-84.24%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Immatics Stock including INR - Dollar returns

The Immatics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Immatics investment value today

Current value as on today

₹1,54,982

Returns

₹54,982

(+54.98%)

Returns from Immatics Stock

₹41,390 (+41.39%)

Dollar Impact

₹13,592 (+13.59%)

Analyst Recommendation on Immatics Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Immatics. Average target price of $17.87

Immatics Share Price Target

Get share price movements and forecasts by analysts on Immatics.

What analysts predicted

49.92%UPSIDE

Target Price

$17.87

Current Price

$8.95

Analyzed by

4 Analysts

Target

$17.87

Immatics target price $17.87, a slight upside of 49.92% compared to current price of $8.95. According to 4 analysts rating.

Indian Investors' Interest in Immatics Stock

Search interest for Immatics Stock has increased by 59% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:59% versus previous 30 day period

Immatics Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
15
30
18
50
56
18
4
5
19
7
Gross Profit
-17
-1
18
50
56
18
4
5
19
7
Operating Income
-27
-13
-26
0
0
-35
-53
-54
-38
-66
EBITDA
-24
-10
-14
0
46
-37
-68
-47
-32
-54
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
1
3
3
3
3
3
3
3
3
2
Income Before Tax
-26
-1
-17
-2
43
-40
-71
-50
-35
-57
Income Tax Expense
-
1
0
6
-1
0
-1
0
0
0
Net Income
-26
-3
-18
-8
44
-39
-70
-50
-35
-57
Net Profit Margin
-108.95%
-5.45%
99.49%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

Immatics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
3
18
31
34
172
53
155
48
Gross Profit
-30
-21
-35
-52
66
-64
155
48
Operating Income
-34
-33
-69
-86
29
-101
-38
-182
EBITDA
-31
-28
-207
-87
50
-88
34
-185
Interest Expense
0
0
0
0
1
0
0
0
Depreciation
2
3
4
5
6
7
12
12
Income Before Tax
-32
-32
-229
-93
42
-96
21
-198
Income Tax Expense
-
-
0
-
4
-
6
-1
Net Income
-31
-31
-229
-95
37
-96
15
-196
Net Profit Margin
-801.09%
-117.31%
-114.65%
-151.92%
38.22%
-119.76%
100.00%
100.00%

Immatics Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-26
-3
-18
-8
44
-39
-70
-52
-35
-58
Operating Cash Flow
79
-32
-33
-33
-58
-34
-39
-44
-57
-42
Investing Cash Flow
59
-241
69
67
-47
46
64
122
-29
-28
Financing Cash Flow
0
174
0
0
146
0
0
0
98
21
Change in Cash
135
-96
36
31
47
6
13
78
10
-51

Immatics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-32
-32
-229
-93
37
-94
15
-188
Operating Cash Flow
20
70
-85
-81
100
18
-158
-169
Investing Cash Flow
-13
-5
-15
7
-209
-31
-152
196
Financing Cash Flow
23
-1
207
-2
123
84
319
93
Change in Cash
30
63
104
-74
15
69
18
137

Mutual Funds that own Immatics Stock

Check out the Mutual Funds with significant holdings in Immatics.

Funds
Holdings
Shares Held
T. ROWE PRICE SMALL-CAP STOCK FUND, INC.
3.915205%
5250156
T. ROWE PRICE SMALL-CAP VALUE FUND, INC.
3.503643%
4698266
T. Rowe Price Equity Funds, Inc.
2.128822%
2854678
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
0.36943%
495393
WASATCH FUNDS TRUST
0.338962%
454537
See all

Global Institutional Holdings in Immatics

Funds
Holdings
Felix Baker
8.14%
Joseph Edelman
7.74%
Michael Rockefeller
0.75%
State Street
0.18%
SPDR
0.13%
See all

Insights on Immatics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 7.61M → 9.29M (in $), with an average increase of 18.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 480.4% return, outperforming this stock by 428.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 608.9% return, outperforming this stock by 640.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -35.69M → -63.52M (in $), with an average decrease of 35.9% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, IMTX stock has moved down by -9.4%

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
OrganisationImmatics
HeadquartersPaul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076
IndustryBiotechnology
CEODr. Harpreet Singh Ph.D.
E-voting on sharesClick here to vote

Key Management of Immatics

Name

Title

Dr. Venkat Ramanan Ph.D.

Chief Financial Officer

Ms. Amie Krause

Chief People Officer

Dr. Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

Dr. Rainer Kramer Ph.D.

Chief Business Officer & Site Head Munich

Dr. Harpreet Singh Ph.D.

CEO, MD, Member of Management Board & Executive Director

Mr. Steffen Walter Ph.D.

Chief Operations Officer

Mr. Ephraim Hofsäß M.Sc.

Vice President of SEC Reporting & Accounting

Ms. Lauren Schroeder

Vice President of Marketing

Dr. Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

Dr. Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

FAQs

What is Immatics share price today?

Immatics share price today is $8.95 as on at the close of the market. Immatics share today touched a day high of $9.03 and a low of $8.62.

What is the 52 week high and 52 week low for Immatics share?

Immatics share touched a 52 week high of $12.41 on and a 52 week low of $5.05 on . Immatics stock price today i.e. is closed at $8.95,which is 27.88% down from its 52 week high and 77.23% up from its 52 week low.

What is Immatics's market capitalisation today?

Immatics market capitalisation is $0.00T as on .

How to invest in Immatics Stock (IMTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immatics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immatics Shares that will get you 0.1676 shares as per Immatics share price of $8.95 per share as on August 22, 2026 at 1:29 am IST.

What is the minimum amount required to buy Immatics Stock (IMTX) from India?

Indian investors can start investing in Immatics (IMTX) shares with as little as ₹95.685 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.85 in Immatics stock (as per the Rupee-Dollar exchange rate as on ). Based on Immatics share’s latest price of $8.95 as on August 22, 2026 at 1:29 am IST, you will get 1.1173 shares of Immatics. Learn more about fractional shares .

What are the returns that Immatics has given to Indian investors in the last 5 years?

Immatics stock has given -22.24% share price returns and 29.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?